Zimmer Biomet, RevelAi Health announce co-marketing agreement for health equity solutions
Click Here to Manage Email Alerts
Key takeaways:
- Zimmer Biomet and RevelAi Health announced a co-marketing agreement.
- Zimmer Biomet will commercialize generative AI-powered value-based care and health equity solutions from RevelAi Health.
Zimmer Biomet and RevelAi Health announced a multi-year co-marketing agreement for generative AI-powered value-based care and health equity solutions, according to a company press release.
“Leveraging generative AI to streamline clinical care workflows while addressing sociodemographic disparities is a unique opportunity to drive equitable value-based
outcomes,” Christian A. Péan, MD, MS, CEO of RevelAi Health and orthopedic trauma surgeon at Duke University School of Medicine, said in the release. “Our AI-enabled asynchronous care model delivers personalized, timely and effective patient care while reducing clinician burnout. Our collaboration with Zimmer Biomet is a significant step toward ensuring that every patient receives the care they deserve.”
According to the release, Zimmer Biomet will commercialize RevelAi Health’s patient care management platform that utilizes text messaging and a clinician-guided voice agent, as well as a care team dashboard for providers.
“Making orthopedic care more accessible and providing innovative solutions that meet
both the clinical and social needs of the communities we serve are key to improving
health outcomes,” Edmond Davis, senior director of health equity at Zimmer Biomet, said in the release. “Teaming up with RevelAi allows us to combine our innovative technologies and shared objective to address the needs of underserved and vulnerable populations, while helping clinicians optimize value-based outcomes.”
Read more about
Click Here to Manage Email Alerts